2015
DOI: 10.1158/1078-0432.ccr-14-3130
|View full text |Cite
|
Sign up to set email alerts
|

CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors

Abstract: The article by Rodig and colleagues, which was published in the August 15, 2009, issue of Clinical Cancer Research, helped detail the clinicopathologic profile of ALK-positive tumors and initiated the development of ALK diagnostics. Subsequent clinical trials utilized these findings, resulting in the approval of effective targeted therapies. The ALK story is a model for the development of therapies in the genomic era. Clin Cancer Res; 21(23); 5185–7. ©2015 AACR. See related article by Rodig et a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
0
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 20 publications
(20 reference statements)
2
0
0
Order By: Relevance
“…The results indicate that our model successfully identifies regions with signet ring cells (Fig- ures 8a and d), a histological feature commonly associated with ALK-rearranged adenocarcinoma 27,28 . Additionally, the model detects regions with a solid growth pattern (Figures 8b and c), which has been previously linked to ALK-rearrangement in other studies 26,29 .…”
Section: Multiple Instance Mnistsupporting
confidence: 64%
“…The results indicate that our model successfully identifies regions with signet ring cells (Fig- ures 8a and d), a histological feature commonly associated with ALK-rearranged adenocarcinoma 27,28 . Additionally, the model detects regions with a solid growth pattern (Figures 8b and c), which has been previously linked to ALK-rearrangement in other studies 26,29 .…”
Section: Multiple Instance Mnistsupporting
confidence: 64%
“…ALK rearrangements were apparently confined to a subset of peritoneal mesotheliomas and not detected in pleural mesotheliomas in this and other studies (9,21,23). ALK, located on chromosome 2p23, is a pivotal therapeutic target with the use of the small-molecule tyrosine-kinase inhibitor in patients with non-small-cell lung cancers, lymphomas, and other rare soft tissue tumors with ALK rearrangements (24,25). Identification of ALK rearrangement suggests that a subset of patients with peritoneal mesothelioma may be identified by immunohistochemistry for ALK and considered for tyrosine-kinase inhibitor therapy.…”
Section: Alk Rearrangements In Peritoneal Mesotheliomasupporting
confidence: 50%